Mental health disorders are among the leading cause of disability worldwide, as well as a strong risk factor for suicides and all-cause mortality. The Global burden disease study 2019 showed that mental disorders remained among the top ten leading causes of burden worldwide, with no evidence of global reduction in the burden since 1990. Even low prevalence psychiatric disorders like Schizophrenia, cause significant disability and pose high emotional and cost burden due to reduced life expectancy, and high cardiovascular mortality associated with the disease. Availability of medications to treat depression, anxiety, and psychotic disorders has helped reducing some of these burdens as well as improving quality of life of individuals with these disorders. Evidence shows that despite good initial responses to treatments to some of these disorders, especially Schizophrenia, recovery rates are much lower. One of the crucial factors in recovery is adherence to treatment and continuation of medications. Nonadherence rates vary from 25-50% depending on the disease. Nonadherence has been strongly linked to high relapse rates, repeated hospitalizations, increased ER visits due to crisis as well as worsening prognosis and poor response to treatment in future. Another important issue would be role of nonadherence in so called treatment resistant and its implications.
The goal of this topic collection is to examine complexities behind medication compliance in psychiatric disorders including patient related, treatment related, and environmental/social factors. We also to seek to examine and highlight research on both positive and negative predictors of adherence, including experimental, theoretical, and longitudinal evidence.
The aim is to build a cohesive understanding of psychiatric treatment adherence with focus on research on facilitators and barriers to adherence and research on strategies to improve it. The prime focus is to assess how patterns of medication adherence related to psychiatric patients’ stability, frequency and intensity of episodes, resistance to treatment, and overall quality of life by highlighting research showing improved measured outcomes with changes in adherence.
Papers that take an experimental approach to improving adherence in psychiatric medication will be giving priority. We welcome empirical research, experimental studies, theoretical frameworks, meta-analyses, and comprehensive reviews.
All papers must include the following:
1. A discussion on a psychiatric treatment
2. An exploration of, and a clear definition, of adherence
3. Specifically mention at least one psychiatric illness
Keywords:
Medication adherence, schizophrenia, recovery, social psychiatry
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Mental health disorders are among the leading cause of disability worldwide, as well as a strong risk factor for suicides and all-cause mortality. The Global burden disease study 2019 showed that mental disorders remained among the top ten leading causes of burden worldwide, with no evidence of global reduction in the burden since 1990. Even low prevalence psychiatric disorders like Schizophrenia, cause significant disability and pose high emotional and cost burden due to reduced life expectancy, and high cardiovascular mortality associated with the disease. Availability of medications to treat depression, anxiety, and psychotic disorders has helped reducing some of these burdens as well as improving quality of life of individuals with these disorders. Evidence shows that despite good initial responses to treatments to some of these disorders, especially Schizophrenia, recovery rates are much lower. One of the crucial factors in recovery is adherence to treatment and continuation of medications. Nonadherence rates vary from 25-50% depending on the disease. Nonadherence has been strongly linked to high relapse rates, repeated hospitalizations, increased ER visits due to crisis as well as worsening prognosis and poor response to treatment in future. Another important issue would be role of nonadherence in so called treatment resistant and its implications.
The goal of this topic collection is to examine complexities behind medication compliance in psychiatric disorders including patient related, treatment related, and environmental/social factors. We also to seek to examine and highlight research on both positive and negative predictors of adherence, including experimental, theoretical, and longitudinal evidence.
The aim is to build a cohesive understanding of psychiatric treatment adherence with focus on research on facilitators and barriers to adherence and research on strategies to improve it. The prime focus is to assess how patterns of medication adherence related to psychiatric patients’ stability, frequency and intensity of episodes, resistance to treatment, and overall quality of life by highlighting research showing improved measured outcomes with changes in adherence.
Papers that take an experimental approach to improving adherence in psychiatric medication will be giving priority. We welcome empirical research, experimental studies, theoretical frameworks, meta-analyses, and comprehensive reviews.
All papers must include the following:
1. A discussion on a psychiatric treatment
2. An exploration of, and a clear definition, of adherence
3. Specifically mention at least one psychiatric illness
Keywords:
Medication adherence, schizophrenia, recovery, social psychiatry
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.